CD40 and neoplasm: In view of the outcome of the in vivo immunization assays and our interest in identifying combinatorial regimens for pancreatic cancer, we proceeded by testing the combination of MEKi and agonist anti-CD40 Abs in three different syngeneic tumor models, including a newly developed K-ras driven model for PDA.